Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Respiratory Cardiovascular Companies

Lupin to market Forest's AeroChamber Plus in the US

This article was originally published in Scrip

Executive Summary

Lupinhas signed a multi-year agreement with Forest Laboratoriesto promote and market Forest's AeroChamber Plus line of products in the US. AeroChamber Plus is a valved holding chamber (VHC) device that is used with metered dose inhalers to improve the delivery of medication to the lungs in the treatment of asthma and chronic obstructive pulmonary disease. Lupin's US subsidiary will use its 50-person sales force to promote the product to paediatricians. The company also expects the alliance to help extend its presence in the respiratory segment and strengthen its franchise with paediatricians. AeroChamber Plus is the most widely prescribed holding chamber in the US and about two thirds of AeroChamber Plus VHC prescriptions (IMS 2007) are written by paediatricians.

Table

View full table

Topics

Related Companies

Tags:
Respiratory Cardiovascular Companies
Latest Headlines

Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways

Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call

Astellas Stakes Claim In CAR-Ts For Solid Tumors With Poseida Deal

Pharma Happy To Be Custodian For Innovative Science From Cash-Strapped Biotechs

See All
UsernamePublicRestriction

Register

SC031173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By